We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
On the Frontiers of Breast Cancer Diagnosis and Treatment: Current and Future Directions in a Rapidly Changing Field.
- Authors
Efird, Jimmy T.; Jindal, Charulata; Biswas, Tithi
- Abstract
Multiple drug resistance and the presentation of unwanted side effects, attributable to inadequate drug concentrations at the tumor site, has limited the effectiveness of various BCa drugs. On the treatment side, both immune checkpoint inhibitors (targeting programmed death protein-1/programmed death protein-ligand 1) and tumor-infiltrating lymphocytes have demonstrated clinical benefit in BCa, especially TNBC disease [[13]]. 33575071 12 McNulty R. 2020 Brings 3 Drugs: How the Breast Cancer Treatment Landscape Has EvolvedAvailable online: https://www.ajmc.com/view/how-the-breast-cancer-treatment-landscape-has-evolved(accessed on 24 July 2022) 13 Qi Y., Zhang L., Wang Z., Kong X., Zhai J., Fang Y., Wang J. Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. Breast cancer (BCa) represents a medically heterogeneous group of malignancies, with differing biological and genetic makeups [[1]].
- Subjects
CANCER diagnosis; TRIPLE-negative breast cancer; CANCER treatment; METASTATIC breast cancer; CIRCULATING tumor DNA
- Publication
Medicina (1010660X), 2022, Vol 58, Issue 8, p1026
- ISSN
1010-660X
- Publication type
Article
- DOI
10.3390/medicina58081026